Danbury bioscience firm Biodel Inc. got a second $582,763 federal grant to fund ongoing development of drug formulations for an artificial pancreas for diabetics.
Biodel said the National Institutes of Health's Small Business Innovation Research program awarded the two-year grant for the development of novel and stable glucagon formulations for use in the device, also known as a closed loop pump system.
The human pancreas dispenses the enzyme glucagon to raise low blood-sugar levels, which can be life threatening to diabetes sufferers.
In July, Biodel announced its first two-year, $582,473 NIH grant to devise a fast-acting synthetic insulin for the artificial pancreas.
Biodel President and CEO Errol De Souza, M.D., said the company has a great deal of expertise in developing stable glucagon formulations for the treatment of severe hypoglycemia
Biodel set early 2014 as the timetable for submitting a new drug application for its synthetic insulin and glucagon formulations.